February 22, 2018 / 9:44 PM / 7 months ago

BRIEF-Corcept Therapeutics Q4 GAAP Earnings Per Share $0.77

Feb 22 (Reuters) - Corcept Therapeutics Inc:

* CORCEPT THERAPEUTICS ANNOUNCES 2017 FINANCIAL RESULTS AND POSITIVE INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL

* SEES FY 2017 REVENUE $159.2 MILLION

* QUARTERLY NON-GAAP NET INCOME PER SHARE $0.19

* Q4 EARNINGS PER SHARE VIEW $0.18, REVENUE VIEW $53.7 MILLION — THOMSON REUTERS I/B/E/S

* CORCEPT THERAPEUTICS - ‍ INTERIM RESULTS OF RELACORILANT PHASE 2 TRIAL SHOW NO EVIDENCE OF PROGESTERONE RECEPTOR AFFINITY; NO SERIOUS ADVERSE EVENTS​

* ‍ RELACORILANT TRIAL SHOWS STATISTICALLY SIGNIFICANT, DOSE-DEPENDENT IMPROVEMENTS IN GLUCOSE TOLERANCE , SERUM OSTEOCALCIN​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below